Status:
TERMINATED
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Eligibility:
All Genders
Up to 24 years
Phase:
NA
Brief Summary
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from...
Detailed Description
OBJECTIVES: Primary * Determine whether granulocyte engraftment can be achieved by day 30 in patients with hematologic disorders undergoing HLA-matched, related-donor, allogeneic bone marrow transpl...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of hematologic malignancy or nonmalignancy
- Candidate for matched, related-donor, allogeneic bone marrow transplantation
- Availability of an HLA-matched (6/6) related donor
- PATIENT CHARACTERISTICS:
- Performance status
- ECOG 0-2 OR
- Karnofsky or Lansky 70-100%
- Life expectancy
- At least 12 weeks
- Hematopoietic
- Not specified
- Hepatic
- Not specified
- Renal
- Not specified
- Other
- No significant functional deficit of any major organ
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- No prior stem cell transplantation
Exclusion
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00253552
Start Date
May 1 2004
End Date
May 1 2006
Last Update
May 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239-3098